Despite all the progress achieved since Scribner first introduced the arteriovenous (AV)
shunt in 1960 and Cimino and Brescia introduced the native AV fistula in 1962, we have …

Paclitaxel (Taxol), one of the most important anticancer drugs, has been used for therapy of
different types of cancers. Mechanistically, paclitaxel arrests cell cycle and induces cell …

Aims Drug-coated balloon catheters (DCB) are a new clinical treatment modality for
coronary and peripheral artery disease. The goal of the consensus group is to develop …

Objective An endovascular-first approach is usually recommended in femoropopliteal
occlusive disease. However, despite high technical success, plain old balloon angioplasty …

Purpose To report the 6-month results of a prospective randomized trial investigating
angioplasty with paclitaxel-coated balloons (PCB) vs. plain balloon angioplasty (BA) for the …

PURPOSE: To evaluate the performance of a heparin-bonded, expanded
polytetrafluoroethylene (ePTFE)–lined nitinol endoprosthesis in the treatment of long …

From early in the history of percutaneous cardiovascular intervention, restenosis has been
one of the most important clinical and biological measures of success, and a great deal of …

Purpose: To evaluate the safety and efficacy of the novel Passeo-18 Lux paclitaxel-coated
balloon compared with the Passeo-18 uncoated balloon in patients with symptomatic de …

Background and objective: Restenosis‐rate after balloon‐angioplasty of long segment tibial
arterial disease is largely unknown. We investigated the restenosis‐rates angiographically …

Peripheral artery disease affects over eight million Americans and is associated with an
increased risk of mortality, cardiovascular disease, functional limitation, and limb loss. In its …